The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Bay-Y3118     8-chloro-1-cyclopropyl-7- [(1S,6R)-5,8...

Synonyms: CCRIS 8689, SureCN1857905, AC1L3OOZ, Bay Y3118, LS-140030, ...
This record was replaced with 119375.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of BAY-Y-3118

 

High impact information on BAY-Y-3118

  • Sparfloxacin, levofloxacin, and Bay y 3118 were active against all aerobic isolates (MICs at which 90% of the isolates are inhibited [MIC90], < or = 1.0 microgram/ml for sparfloxacin and levofloxacin and 0.1 microgram/ml for Bay y 3118) and many anaerobic isolates, with the exception of the fusobacteria [6].
  • Toxicity problems have necessitated the withdrawal of some quinolones shown to have intermediate activity (temafloxacin and tosufloxacin) and the discontinuation of the development of some investigational agents (Win 57273 and BAY Y 3118) with high activity [7].
  • Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes [5].
  • Bay Y 3118 completely eliminated L. monocytogenes from the livers and spleens of chronically infected nude mice [4].
  • The intracellular penetration of BAY Y 3118 was significantly affected by environmental temperature (C/E ratio at 4 degrees C, 5.4 +/- 0.5; control, 7.5 +/- 0.9; P < 0.05) and cell viability (C/E ratio in dead PMNs, 5.5 +/- 0.8; control 7.5 +/- 0.9; P < 0.05), but it was not affected by metabolic inhibitors [5].
 

Chemical compound and disease context of BAY-Y-3118

 

Anatomical context of BAY-Y-3118

  • Human monocyte-derived macrophages were infected with M. avium strain 101 and a quinolone (Bay y 3118) was used at 8 micrograms ml-1, a concentration that kills growing bacteria but fails to eliminate static organisms [9].
 

Associations of BAY-Y-3118 with other chemical compounds

 

Analytical, diagnostic and therapeutic context of BAY-Y-3118

  • Bay Y 3118 was tested in vitro and in animal models of listeriosis [4].
  • Determination of BAY y 3118, a novel 4-quinolone, in biological fluids using high-performance liquid chromatography and photothermal post-column derivatization [10].
  • A reversed-phase high-performance liquid chromatographic (HPLC) method that allows the sensitive and selective quantification of a novel 4-quinolone (BAY y 3118, I) in biological fluids is described [10].
  • [K.D. Bremm, U. Petersen, K.G. Metzger, R. Endermann, In vitro evaluation of Bay-y 3118, a new full-spectrum fluoroquinolone, Chemotherapy 38 (1992) 376-387] was injected into fertilized turkey eggs 8 days before hatching at doses of 1, 3, 10 and 30 mg per egg [11].
  • Pharmacokinetic and clinical trials are required to define the role of BAY y 3118 in the treatment of anaerobic infections [12].

References

  1. In vitro activity of Bay Y3118 against anaerobic bacteria. Wexler, H.M., Molitoris, E., Finegold, S.M. Antimicrob. Agents Chemother. (1993) [Pubmed]
  2. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Aldridge, K.E. Antimicrob. Agents Chemother. (1994) [Pubmed]
  3. In vitro activity of Bay y 3118, a new quinolone. Fass, R.J. Antimicrob. Agents Chemother. (1993) [Pubmed]
  4. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Nichterlein, T., Kretschmar, M., Budeanu, C., Bauer, J., Linss, W., Hof, H. Antimicrob. Agents Chemother. (1994) [Pubmed]
  5. Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. García, I., Pascual, A., Perea, E.J. Antimicrob. Agents Chemother. (1994) [Pubmed]
  6. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Goldstein, E.J., Nesbit, C.A., Citron, D.M. Antimicrob. Agents Chemother. (1995) [Pubmed]
  7. Quinolone activity against anaerobes: microbiological aspects. Appelbaum, P.C. Drugs (1995) [Pubmed]
  8. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Dalhoff, A. Clin. Infect. Dis. (2001) [Pubmed]
  9. Isolation of two subpopulations of Mycobacterium avium within human macrophages. Bermudez, L.E., Wu, M., Miltner, E., Inderlied, C.B. FEMS Microbiol. Lett. (1999) [Pubmed]
  10. Determination of BAY y 3118, a novel 4-quinolone, in biological fluids using high-performance liquid chromatography and photothermal post-column derivatization. Schaefer, H.G. J. Chromatogr. (1993) [Pubmed]
  11. Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver. Enzmann, H., Wiemann, C., Ahr, H.J., Schlüter, G. Mutat. Res. (1999) [Pubmed]
  12. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria. García-Rodríguez, J.A., García-Sánchez, J.E., Trujillano-Martín, I., García-Sánchez, E., García-García, M.I., Fresnadillo-Martínez, M.J. Journal of chemotherapy (Florence, Italy) (1995) [Pubmed]
 
WikiGenes - Universities